Tandem Diabetes Care Acquires Infusion Set Developer, Capillary Biomedical

0

SAN DIEGO–(BUSINESS WIRE)–$TNDM–Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes treatment technology company, today announced its acquisition of infusion set developer, Capillary Biomedical.

“Infusion sets give people flexible options for insulin pump portability, and we are committed to expanding our portfolio of sets to give our customers even greater choice in customizing their management system. therapy,” said John Sheridan, president and CEO of Tandem Diabetes Care. “Through this acquisition and our efforts with existing infusion set partners, we look forward to developing new, innovative infusion set solutions designed to extend wear time and improve user experience, while reducing occlusions, body burden and waste.”

Capillary Biomedical’s unique extended wear infusion set technology is currently under development and not commercially available. Financial terms were not disclosed.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc., a global diabetes and insulin delivery technology company based in San Diego, California, is creating new possibilities for people with diabetes, their loved ones and healthcare providers through to a positively different experience. The company’s human-centered approach to design, development and support delivers innovative products and services to people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. For more information, visit tandemdiabetes.com.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2 and $TNDM.

Follow Tandem Diabetes Care on Facebook at facebook.com/TandemDiabetes.

Follow Tandem Diabetes Care on LinkedIn at linkedin.com/company/tandemdiabetes.

© 2022 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, Control-IQ and t:slim X2 are registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. All third-party trademarks are the property of their respective owners.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that relate to matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements relate to, among other things, the Company’s future development of new diabetes-related products and services, the advancement of the Company’s infusion set offering, including its continued development and the introduction of a extended wear infusion set, the Company’s ability to successfully obtain FDA approval for its infusion set and the timing of the infusion set’s launch. These statements are subject to numerous risks and uncertainties, including the Company’s ability to innovate and manage its growth, the Company’s ability to successfully integrate Capillary Biomedical’s products and infusion set designs into the products and services related to the Company’s diabetes, the Company’s ability to manufacture and launch the Capillary Biomedical infusion set, and uncertainties regarding market conditions impacting the Company’s business and industry, as well as other risks identified in our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and other documents we file with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or revise any forward-looking statements contained in this press release as a result of new information, future events or other factors.

contacts

Media Contact:
Steve Sabicer

714-907-6264

ssabicer@thesabicergroup.com

Investor contacts:
Susan Morrison

858-366-6900

IR@tandemdiabetes.com

Copyright © acrofan/Business Wire All Rights Reserved



Source link

Share.

Comments are closed.